Delivering Improved Cardiac Safety Liabilities for Therapeutic Drugs Using the Contractome-AI

使用 Contractome-AI 改善治疗药物的心脏安全责任

• 批准号: 95209
• 金额: $ 6.37万
• 依托单位: INOCARDIA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=95209
• 关键词: Delivering; Improved; Cardiac; Safety; Liabilities

As the founder of InoCardia Ltd, I have applied 30 years' experience aligned to the pharmaceutical industry to commercialise the cardiac Work-Loop contractility platform as a spin-out company from Coventry University in 2013\.The commercialisation of my academic research started with a vision that there was a fundamental need within the Pharmaceutical Industry for the development of improved physiological relevant model to assess cardiac contractility. These discussions underpinned academic research projects leading to the development of the novel tissue/cell-based Work-Loop Platform that opened-up new pathways to safer drug development. The Work-Loop Platform was commercialised through the formation of the spin-out company InoCardia Ltd, focussing on providing a cardiac drug safety assessment service. Customers have included global pharmaceutical companies and drug discovery biotechs. The company has generated UK & EU investment funding from external funding bodies (i.e InnovateUK) and venture capitalists. The company currently offers the world's first nonclinical contractility assay which offers superior predictivity and is currently revolutionising the field of cardiac safety assessment. There is a lot to learn to translate an academic research idea into a robust commercial offering, in addition to accessing external funding, protecting intellectual property, getting buy-in from stakeholders, learning the language of business and understanding market requirements and dynamics.The notion of being a role model not only to my two children but also students in Schools and at University is extremely important to me. I truly believe that the "world should be your oyster". I am passionate about Business/Research inspired teaching and currently teach "How to form a spin out company", on BSc/MSc programmes. I see this award as an opportunity to enable me to inspire female scientists towards business innovation. Although I am the founder and current CSO for InoCardia, I stepped down from being InoCardia's CEO 3 years ago as I didn't feel that I had the confidence or adequate business experience to be CEO for my company. I see the Women in Innovation award an important supportive route to gain necessary skills to progress to CEO in the future. I think support via this award will not only help give me more confidence in my abilities as a leader and tech innovator but also helped raise the company's profile. It will enable me to promote InoCardia's vision within the Pharmaceutical Industry and provide me with the access to a network of business support, networking events and attract further investment.

作为InoCardia Ltd的创始人，2013年，我将30年的制药行业经验应用于心脏Work-Loop收缩平台的商业化，作为考文垂大学的一家分拆公司。。我的学术研究的商业化始于一个愿景，即制药行业对开发改进的生理相关模型以评估心脏收缩性这些讨论支持了学术研究项目，导致开发了基于组织/细胞的新型工作循环平台，为更安全的药物开发开辟了新的途径。Work-Loop平台通过分拆公司InoCardia Ltd的成立而商业化，专注于提供心脏药物安全性评估服务。客户包括全球制药公司和药物发现生物技术公司。该公司已经从外部融资机构（即InnovateUK）和风险投资家那里获得了英国和欧盟的投资资金。该公司目前提供世界上第一个非临床收缩性测定，提供上级预测性，目前正在彻底改变心脏安全评估领域。除了获得外部资金，保护知识产权，获得利益相关者的支持，学习商业语言，了解市场需求和动态。不仅是我的两个孩子，而且是学校和大学学生的榜样，这对我来说非常重要。我真的相信，“世界应该是你的牡蛎”我热衷于商业/研究启发教学，目前教“如何形成一个分拆公司”，在BSC/MSC程序。我认为这个奖项是一个机会，使我能够激励女性科学家走向商业创新。虽然我是InoCardia的创始人和现任CSO，但3年前我辞去了InoCardia的首席执行官一职，因为我觉得自己没有信心或足够的商业经验担任公司的首席执行官。我认为创新女性奖是一条重要的支持途径，可以帮助您获得未来晋升为首席执行官所需的技能。我认为通过这个奖项的支持不仅有助于让我对自己作为领导者和技术创新者的能力更有信心，而且还有助于提高公司的知名度。它将使我能够促进InoCardia在制药行业的愿景，并为我提供访问业务支持网络、网络活动和吸引进一步投资的机会。